ASND
Ascendis Pharma A/S
NASDAQ · DKHealthcareBiotechnology
$251.76-3.54%
Price as of Jul 20, 2026
ASND financials
Ascendis Pharma A/S financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $691.7M | $363.6M | $266.7M | $51.2M |
| Cost of revenue | $103.2M | $44.3M | $44.4M | $12.1M |
| Gross profit | $588.5M | $319.4M | $222.3M | $39.0M |
| Operating expenses | $719.4M | $598.1M | $677.9M | $600.9M |
| Operating income | -$130.9M | -$278.8M | -$455.5M | -$561.8M |
| Net income | -$219.0M | -$378.1M | -$481.4M | -$583.2M |
| EBITDA | -$109.8M | -$290.0M | -$411.2M | -$529.2M |
| Basic EPS | $-3.62 | $-6.53 | $-8.55 | $-10.40 |
| Diluted EPS | $-3.62 | $-6.53 | $-8.55 | $-10.40 |
| Balance sheet | ||||
| Cash & equivalents | $615.8M | $559.5M | $392.2M | $444.8M |
| Total assets | $1.3B | $1.2B | $825.6M | $1.1B |
| Total liabilities | $1.5B | $1.3B | $971.3M | $826.4M |
| Stockholders’ equity | -$162.8M | -$105.7M | -$145.7M | $263.3M |
| Total debt | $871.4M | $856.6M | $743.1M | $617.6M |
| Net debt | $255.6M | $297.1M | $350.9M | $172.8M |
| Cash flow | ||||
| Operating cash flow | $51.8M | -$306.2M | -$467.4M | -$495.7M |
| Capital expenditure | -$8.2M | -$1.4M | -$2.4M | -$14.5M |
| Free cash flow | $43.6M | -$307.6M | -$469.8M | -$510.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$16.7M | $0.00 | -$1.8M | -$105.3M |